112 210

Cited 30 times in

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

DC FieldValueLanguage
dc.contributor.author김수희-
dc.contributor.author김효송-
dc.contributor.author라선영-
dc.contributor.author신규호-
dc.contributor.author조용진-
dc.date.accessioned2016-02-04T11:23:33Z-
dc.date.available2016-02-04T11:23:33Z-
dc.date.issued2015-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/140322-
dc.description.abstractBACKGROUND: We retrospectively reviewed outcomes of treatment with pazopanib, an oral multi-tyrosine kinase angiogenesis inhibitor, in patients with advanced soft tissue sarcoma, a rare and heterogeneous tumor group with limited treatment options. METHODS: Between 2009 and 2013, 43 patients with metastatic soft tissue sarcoma received pazopanib as salvage chemotherapy after one or more cytotoxic regimens. Response rate, progression-free survival, and overall survival were analyzed according to histological subtype, Eastern Cooperative Oncology Group performance status, and metastatic site. RESULTS: Common histological subtypes included leiomyosarcoma (n = 9), angiosarcoma (n = 6), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (MFH/UPS, n = 5), malignant peripheral nerve sheath tumor (MPNST, n = 5), and synovial sarcoma (n = 4). Nineteen patients (44.2%) received more than two chemotherapy regimens before pazopanib. At the time of analysis, 208 treatment cycles of pazopanib had been administered (median, 4.8 cycles per patient), and no treatment-related mortality occurred. The disease control rate was 61.0% (95% confidence interval [CI], 46.1-75.9%), and the overall response rate was 17.1% (partial response, n = 7; complete response, n = 0). Partial response was achieved in two patients with synovial sarcoma, two with MFH/UPS, one with MPNST, one with leiomyosarcoma, and one with angiosarcoma. The median lengths of progression-free survival and overall survival were 5.0 months (95% CI, 3.6-6.4 months) and 8.2 months (95% CI, 5.8-10.6 months), respectively. Progression-free survival was shorter in the patients with liposarcoma and rhabdomyosarcoma (1.3 and 0.9 months, respectively) than in those with leiomyosarcoma, MPNST, MFH/UPS, and synovial sarcoma (5.6, 6.5, 7.1, and 7.7 months, respectively). CONCLUSIONS: Pazopanib demonstrated acceptable antitumor activity in the Asian patients who had been heavily pretreated for sarcoma, with seemingly more favorable results in the patients with leiomyosarcoma, MPNST, MFH/UPS, and synovial sarcoma than in those with liposarcoma and rhabdomyosarcoma.-
dc.description.statementOfResponsibilityopen-
dc.format.extent154-
dc.relation.isPartOfBMC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis/drug therapy*-
dc.subject.MESHNeoplasm Metastasis/pathology-
dc.subject.MESHProtein Kinase Inhibitors/administration & dosage*-
dc.subject.MESHPyrimidines/administration & dosage*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSarcoma/drug therapy*-
dc.subject.MESHSarcoma/pathology-
dc.subject.MESHSulfonamides/administration & dosage*-
dc.titleEfficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorKwai Han Yoo-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorSu Jin Lee-
dc.contributor.googleauthorSe Hoon Park-
dc.contributor.googleauthorSung Joo Kim-
dc.contributor.googleauthorSoo Hee Kim-
dc.contributor.googleauthorYoon La Choi-
dc.contributor.googleauthorKyoo-Ho Shin-
dc.contributor.googleauthorYong Jin Cho-
dc.contributor.googleauthorJeeyun Lee-
dc.contributor.googleauthorSun Young Rha-
dc.identifier.doi10.1186/s12885-015-1160-x-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00644-
dc.contributor.localIdA01202-
dc.contributor.localIdA02086-
dc.contributor.localIdA03867-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00351-
dc.identifier.eissn1471-2407-
dc.identifier.pmid25885855-
dc.subject.keywordHistological type-
dc.subject.keywordPazopanib-
dc.subject.keywordSoft tissue sarcoma-
dc.contributor.alternativeNameKim, Soo Hee-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameShin, Kyoo Ho-
dc.contributor.alternativeNameCho, Yong Jin-
dc.contributor.affiliatedAuthorKim, Soo Hee-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.contributor.affiliatedAuthorShin, Kyoo Ho-
dc.contributor.affiliatedAuthorCho, Yong Jin-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsfree-
dc.citation.volume15-
dc.citation.startPage154-
dc.identifier.bibliographicCitationBMC CANCER, Vol.15 : 154, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.